Influence of ethnicity and improved outcome of acute myeloid leukaemia: two decades of follow-up of Israeli patient cohort.

abstract：:Follicular lymphoma is the most common indolent non-Hodgkin lymphoma. Survival has improved over the last several decades, mainly because of the incorporation of the anti-CD20 antibody rituximab into preexisting or rediscovered agents. The disease has a relapsing and remitting pattern, coupled with a risk of transform...

journal_title：Hematological oncology

authors： Apostolidis J,Mokhtar N,Al Omari R,Darweesh M,Al Hashmi H

更新日期：2020-08-01 00:00:00

abstract：:Continuous administration of amphotericin B deoxycholate over 24 hours (24 h-D-AmB) is better tolerated than rapid infusions. However, toxicity and outcome have not been assessed in a homogenous patient population with acute myeloid leukaemia (AML). We retrospectively analysed renal function and outcome in all adult p...

journal_title：Hematological oncology

authors： Rothenbühler C,Held U,Manz MG,Schanz U,Gerber B

更新日期：2018-04-01 00:00:00

abstract：:Left ventricular stroke distance was measured by Doppler ultrasound in 10 doxorubicin-treated and 10 control patients. Measurements were made 10 min, 2 h and 4 h after drug administration. Stroke distance (a linear analogue of stroke volume) increased significantly from 12.6 cm (S.D. 2.7) before and 12.5 cm (S.D. 2.7)...

journal_title：Hematological oncology

authors： Clive S,Dawson A,Bennett B,Rawles J

更新日期：1991-01-01 00:00:00

abstract：:Twenty-three patients (16 adults) failing their first or subsequent (n = 8) intensive treatment for de novo acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia lymphoid blast phase (n = 2) were managed with protocol POG 8201, originally introduced in relapsed ALL of childhood. In this programme, a four-dru...

journal_title：Hematological oncology

authors： Bassan R,Cornelli PE,Battista R,Terzi F,Buelli M,Rambaldi A,Viero P,D'Emilio A,Dini E,Barbui T

更新日期：1992-03-01 00:00:00

abstract：:The aim of this study was to explore the expression of retinoblastoma protein and EBV status in a cohort of cases of Hodgkin's disease from South Africa. Seventy one cases of Hodgkin's disease were accessed over a 6-year period and were classified according to the Rye Classification. Relevant sections were stained wit...

journal_title：Hematological oncology

authors： Chetty R,Bickhoo A

更新日期：1997-11-01 00:00:00

abstract：:The REAL Classification of lymphomas, proposed in 1994, represents a new paradigm in lymphoma classification, consisting of a list of biologic entities defined by clinicopathologic and immunogenetic features. The non-Hodgkin's lymphomas comprise precursor lymphoblastic and mature cell neoplasms of B, T or putative nat...

journal_title：Hematological oncology

authors： Chan JK

更新日期：2001-12-01 00:00:00

abstract：:A new monoclonal antibody (MAB), IA61gG2a, has been derived from Balb/c mice after immunization with T-cell chronic lymphocytic leukemia (T-CLL). This monoclonal antibody, 1A6 was tested on normal human peripheral blood cells, leukemia patients' cells and leukemia-lymphoma cell lines. The results demonstrated that thi...

journal_title：Hematological oncology

authors： Togashi H,Ghoneum M,Takasugi M,Kasai K,Mugishima H,Billing R,Terasaki PI

更新日期：1989-05-01 00:00:00

abstract：:There have been an increasing number of reports describing a pivotal role for phosphorylation in cellular responses for cell differentiation and proliferation. We examined an immunocytochemical expression of protein kinase C(PKC) isozymes (type I, II, and III) in 22 leukemia-lymphoma cell lines. Of these cell lines, 2...

journal_title：Hematological oncology

authors： Hojo H,Morimura Y,Abe M,Tominaga K,Nozawa Y,Nakamura N,Ono N,Tasaki K,Yamaguchi Y,Suzuki S

更新日期：1992-11-01 00:00:00

abstract：:Therapy with recombinant interleukin-2 (rIL-2) induces clinical response in a significant number of patients with refractory malignant disease. Very few patients with non-Hodgkin's lymphoma (NHL) have been treated with rIL-2. The present study sought to determine if peripheral blood mononuclear cells (PBM) from patien...

journal_title：Hematological oncology

authors： Zamkoff KW,Watman NP,Duggan DB,Poiesz BJ,Gottlieb AJ

更新日期：1990-03-01 00:00:00

abstract：:Based on results of two pilot trials, lenalidomide (LEN) was found to be active and safe as monotherapy and showed an increased response rate of 80% in combination with rituximab (R) for patients with mucosa-associated lymphoid tissue (MALT) lymphoma. While initial results were promising, there are currently no data o...

journal_title：Hematological oncology

authors： Kiesewetter B,Lamm W,Neuper O,Mayerhoefer ME,Simonitsch-Klupp I,Raderer M

更新日期：2019-10-01 00:00:00

abstract：:Acute kidney injury (AKI) is one of the complications of hematopoietic stem cell transplantation and is associated with increased mortality. N-acetylcysteine (NAC) is a thiol compound with antioxidant and vasodilatory properties that has been investigated for the prevention of AKI in several clinical settings. In the ...

journal_title：Hematological oncology

authors： Ataei S,Hadjibabaie M,Moslehi A,Taghizadeh-Ghehi M,Ashouri A,Amini E,Gholami K,Hayatshahi A,Vaezi M,Ghavamzadeh A

更新日期：2015-06-01 00:00:00

abstract：:Recent studies have suggested that chromosomal aberrations of the MYC gene locus indicate an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL). However, there have been few reports on MYC translocation in Chinese patients. One hundred and six cases of DLBCLs were analyzed using interphase fluorescent in s...

journal_title：Hematological oncology

authors： Zhang HW,Chen ZW,Li SH,Bai W,Cheng NL,Wang JF

更新日期：2011-12-01 00:00:00

abstract：:Because of the rarity of the disease, randomized clinical trials for multicentric Castleman disease (MCD) remain a challenge and, as a consequence, there is no established standard of care. Siltuximab is a chimeric immunoglobulin G1κ monoclonal antibody against human IL-6 which was recently approved by FDA. Eligible p...

journal_title：Hematological oncology

authors： Tonialini L,Bonfichi M,Ferrero S,Malipiero G,Nozza A,Argnani L,Zinzani PL

更新日期：2018-10-01 00:00:00

abstract：:In order to develop an effective immunotherapy for hematological malignancies, we investigated the applicability of class II transactivator (CIITA), which had been demonstrated to regulate the expression of MHC class II (MHC-II) by assembling the transcription factors of MHC-II molecules, for immunotherapy by potentia...

journal_title：Hematological oncology

authors： Liu A,Takahashi M,Toba K,Zheng Z,Hashimoto S,Nikkuni K,Furukawa T,Koike T,Aizawa Y

更新日期：1999-12-01 00:00:00

abstract：:The aim of this article is to meta-analyse published data about the detection rate (DR) of fluorine-18-fluorodeoxyglucose ((18) F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) in the evaluation of patients with marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT). A compreh...

journal_title：Hematological oncology

authors： Treglia G,Zucca E,Sadeghi R,Cavalli F,Giovanella L,Ceriani L

更新日期：2015-09-01 00:00:00

abstract：:These are the final results of the Ofatumumab in MALT lymphoma study (O-MA 1), a pilot phase II trial evaluating the capacity and safety of ofatumumab to induce objective responses in patients with Helicobacter pylori eradication refractory or extragastric MALT lymphoma. Ofatumumab was given at 4 weekly doses (1000 mg...

journal_title：Hematological oncology

authors： Kiesewetter B,Neuper O,Mayerhoefer ME,Dolak W,Lukas J,Simonitsch-Klupp I,Raderer M

更新日期：2018-02-01 00:00:00

abstract：:Advanced-stage mycosis fungoides and Sezary syndrome (MF/SS) have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT), particularly using a reduced-intensity conditioning (RIC) regimen, is a promising treatment for advanced-stage MF/SS. We performed RIC-HSCT in nine patients with advanced MF/SS...

journal_title：Hematological oncology

authors： Shiratori S,Fujimoto K,Nishimura M,Hatanaka KC,Kosugi-Kanaya M,Okada K,Sugita J,Shigematsu A,Hashimoto D,Endo T,Kondo T,Abe R,Hashino S,Matsuno Y,Shimizu H,Teshima T

更新日期：2016-03-01 00:00:00

abstract：:Composite plasma cell neoplasm (PCN) and low grade B-cell lymphoma (B-NHL) in the bone marrow are uncommon and raise the differential diagnosis of B-NHL with plasmacytic differentiation and PCN with lymphoplasmacytic morphology. This can be a challenging differential diagnosis, and the distinctions are important becau...

journal_title：Hematological oncology

authors： Hussein S,Gill K,Baer LN,Hoehn D,Mansukhani M,Jobanputra V,Bhagat G,Alobeid B

更新日期：2015-03-01 00:00:00

abstract：:Fourteen patients with poor-risk acute myelogenous leukaemia (AML) and five patients with accelerated phase/blast crisis chronic myeloid leukaemia (CML) were treated with 3 days of oral idarubicin (25 mg/m2/day). No complete remissions or return to chronic phase CML were observed. A fall in the peripheral blast count ...

journal_title：Hematological oncology

authors： Malik ST,Tucker J,Rohatiner AZ,Brace W,Lister TA

更新日期：1989-11-01 00:00:00

abstract：:Langerhans cell histiocytosis (LCH) is rare in adults, and only a subset of these patients suffers from central nervous system (CNS) involvement. Hence, evidence-based treatment recommendations are lacking. A case of a 20-year-old student with multisystem LCH and extensive CNS involvement is described, who showed a du...

journal_title：Hematological oncology

authors： Baumann M,Cerny T,Sommacal A,Koeberle D

更新日期：2012-06-01 00:00:00

abstract：:This is a phase II study of panobinostat, an oral pan-HDAC inhibitor, combined with rituximab in patients with relapsed diffuse large B cell lymphoma. Panobinostat was administered orally 3 times a week every other week on a 28-day cycle. Rituximab was administered weekly during the first cycle, then on Day 1 of cycle...

journal_title：Hematological oncology

authors： Barnes JA,Redd R,Fisher DC,Hochberg EP,Takvorian T,Neuberg D,Jacobsen E,Abramson JS

更新日期：2018-10-01 00:00:00

abstract：:We have treated 11 patients with relapsed or resistant lymphoma with a combination of Etoposide, Prednisolone, Ifosfamide and Carboplatin (EPIC), obtaining complete responses in two patients and partial responses in four patients for an overall response rate of 54 per cent. The treatment was well tolerated with no tox...

journal_title：Hematological oncology

authors： Richardson DS,Tighe M,Cull G,Johnson SA,Phillips MJ

更新日期：1994-05-01 00:00:00

abstract：:The novel human pre-B cell line OZ was established from a patient with an aggressive form of non-Hodgkin's lymphoma. Karyotypic analysis of both the primary tumour and OZ cells revealed several marker chromosomes, including the t(14;18)(q32;q21) translocation, which involves the Bcl-2 gene, and alterations on chromoso...

journal_title：Hematological oncology

authors： Nagai M,Fujita M,Ohmori M,Matsubara S,Taniwaki M,Horiike S,Tasaka T,Koeffler HP,Takahara J

更新日期：1997-08-01 00:00:00

abstract：:Mucosa-associated lymphoid tissue (MALT) lymphoma is a radiosensitive malignancy. We report on a case of severe retinopathy following radiation therapy with a moderate dose for orbital MALT lymphoma. A 69-year-old woman with orbital MALT lymphoma received definitive radiation therapy with a total dose of 36 Gy in 18 f...

journal_title：Hematological oncology

authors： Hata M,Kaneko A,Tomita N,Inoue T

更新日期：2014-12-01 00:00:00

abstract：:For finding better method of acute myeloid leukaemia (AML) induction, we designed a prospective clinical trial to find a more effective regimen with least toxicity for induction therapy of AML. Hence, we examined different accepted doses of daunorubicin and their outcomes. Total of 114 patients were included in the st...

journal_title：Hematological oncology

authors： Vaezi M,Bahar B,Mousavi A,Yaghmai M,Kasaeian A,Souri M,Jahani M,Alimoghaddam K,Ghavamzadeh A

更新日期：2017-03-01 00:00:00

abstract：:This study evaluates response-adapted treatment of chronic myelogenous leukaemia (CML) in chronic phase using molecular response criteria. bcr-abl/G6PDH ratios were assessed by Light-Cycler quantitative real-time polymerase chain reaction (PCR( in 277 peripheral blood samples from 33 patients, before and every 3 month...

journal_title：Hematological oncology

authors： Neumann F,Markett J,Fenk R,Pooten M,Koch A,Bruennert D,Schimkus N,Wulfert M,Royer-Pokora B,Kronenwett R,Haas R,Gattermann N

更新日期：2008-12-01 00:00:00

abstract：:Abdominal presentations of pediatric NHL are rarely amenable to complete surgical resection. Chemotherapy is the hallmark of treatment for pediatric NHL. Treatment of various types of this disease including intra-abdominal NHL in children with various protocols have not exceeded 54 per cent two-year disease-free survi...

journal_title：Hematological oncology

authors： Abdel Hadi SS,el Taneer OM,Hussein MH,el Haddad A,el Badawi S,Mokhtar N,Hamza MR,el Mawla NG

更新日期：1991-07-01 00:00:00

abstract：:Prognoses of persons with chronic lymphocytic leukemia (CLL) including time-to-therapy (TTT) and survival is heterogeneous. Risk factors and predictive scoring systems are mostly developed in persons of predominately European descent with CLL. Whether these systems accurately predict TTT and survival of Han Chinese wi...

journal_title：Hematological oncology

authors： Qin S,Fan L,Liang J,Gale R,Miao Y,Wu Y,Wang R,Yang H,Wu W,Xia Y,Wu J,Zhu H,Wang L,Xu W,Li J

更新日期：2018-10-01 00:00:00

abstract：BACKGROUND:A subset of patients with non-Hodgkin's lymphoma (NHL) with clinical stage I or IE at presentation is left without other NHL localizations following surgery performed for diagnostic histology, and thus without any target lesion to judge the immediate effectiveness of immediately applied additional treatment ...

journal_title：Hematological oncology

authors： Jelić S,Frim O,Gligorijević G,Gavrilović D,Manojlović N,Jovanović V,Oprić M

更新日期：1997-05-01 00:00:00

abstract：:Peripheral blood progenitor cells used during high dose treatments for malignancy may be contaminated with tumour cells that could later contribute to recurrence. CD34+ selected harvests still contain tumour cells and an additional negative selection may be capable of reducing this contamination. We have assessed a tw...

journal_title：Hematological oncology

authors： Davies FE,Rawstron AC,Pratt G,Coupe R,Clarke D,Lubenko A,Short K,Perren TJ,Selby PJ,Maclennan S,Major K,Woodhead V,Robinson F,Child JA,Smith GM,Johnson PW,Morgan GJ

更新日期：2000-09-01 00:00:00